Data updated: Jun 28, 2026
Arrhythmia Clinical Trial Landscape
Arrhythmia is being studied across 83 clinical trials registered since 2008, with 25 programs currently active. The competitive pipeline includes 7 active Phase 3 trials, 8 active Phase 2 trials, and 3 active Phase 1 trials.
Top industry sponsors include Cardurion Pharmaceuticals, Inc., Solid Biosciences Inc., Agiana Pharmaceuticals.
Trial activity
25 active / 83 total since 2008
Active by phase 7 Ph3 / 28 8 Ph2 / 20 3 Ph1 / 6 7 Ph4 / 29
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Cardurion Pharmaceuticals, Inc. 1 0 1
Solid Biosciences Inc. 1 0 0
Agiana Pharmaceuticals 1 0 0
AskBio Inc 1 0 0
Biosense Webster, Inc. 0 2 2
How the field has grown
New-trial starts peaked in 2025 (8 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (15 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 4
2017 4
2018 4
2019 4
2020 3
2021 2
2022 6
2023 7
2024 6
2025 8
2026 2
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (1) 105
2017 (0) 0
2018 (3) 169
2019 (1) 1,116
2020 (1) 68
2021 (1) 130
2022 (3) 244
2023 (0) 0
2024 (3) 210
2025 (2) 483
2026 (0) 0
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07174986 RECRUITING
Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest
Gabriel Riva n=916
NCT06281977 RECRUITING
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
Ottawa Heart Institute Research Corporation n=192
NCT05047198 RECRUITING
Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial
Ottawa Heart Institute Research Corporation n=244
NCT06965998 RECRUITING
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
Ottawa Hospital Research Institute n=50
NCT05890664 RECRUITING
Colchicine After Electrocardioversion for Atrial Fibrillation
University Hospital, Basel, Switzerland n=416
NCT06717685 RECRUITING
Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients
Rashid Latif Medical College n=210
NCT05213104 ACTIVE NOT RECRUITING
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
Assistance Publique - Hôpitaux de Paris n=186
NCT04952610 COMPLETED
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Inc. n=130
NCT04134845 COMPLETED
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Vanderbilt University Medical Center n=68
NCT01898221 COMPLETED
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
The Methodist Hospital Research Institute n=343
NCT01426425 COMPLETED
Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia
Medtronic Cardiac Ablation Solutions n=572
NCT01385202 COMPLETED
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Biosense Webster, Inc. n=172
NCT00721149 TERMINATED
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
Biosense Webster, Inc. n=10
NCT05410860 COMPLETED
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Corxel Pharmaceuticals n=500
NCT03635996 TERMINATED
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Milestone Pharmaceuticals Inc. n=169
NCT03464019 TERMINATED
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
Milestone Pharmaceuticals Inc. n=1,097
NCT04072835 COMPLETED
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Milestone Pharmaceuticals Inc. n=1,116
NCT02624765 COMPLETED
Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)
Edgar Jaeggi n=105
NCT04392362 COMPLETED
A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
University of Pretoria n=30
NCT00789165 WITHDRAWN
Empiric Quinidine for Asymptomatic Brugada Syndrome
International Registry of Asymptomatic Brugada Syndrome
NCT03021343 COMPLETED
Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients
Jordan Collaborating Cardiology Group n=360
NCT01439386 COMPLETED
Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter
Texas Cardiac Arrhythmia Research Foundation n=86
NCT01038960 COMPLETED
Exercise Training in ICD Recipients; Effect on Therapy Delivered, Depression and Anxiety
Helse Stavanger HF n=40
NCT02652338 COMPLETED
Dietary Supplement on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia
Trommsdorff GmbH & Co. KG n=74
NCT01798277 WITHDRAWN
Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia
Newmarket Electrophysiology Research Group Inc
NCT00624520 TERMINATED
Mental Stress Reduction in Defibrillator Patients
US Department of Veterans Affairs n=129
NCT01045668 COMPLETED
Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation
Texas Cardiac Arrhythmia Research Foundation n=120
NCT00749307 COMPLETED
Effects of Docosahexaenoic Acid (DHA) on Heart Rate Variability in Elderly Patients
Campus Bio-Medico University n=50
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only